2011 Scrip 100: Oncology trials
This article was originally published in Scrip
Between 1 October 2009 and 30 September 2010, there were 428 new Phase II to Phase III clinical trials initiated by industry sponsors in the oncology arena. Non-small cell lung cancer was the clear disease focus, accounting for 11% of these new trials. Breast cancer, multiple haematological cancers, non-Hodgkin's lymphoma and colorectal cancer rounded out the top five disease areas, together accounting for 35% (147) of the total trials initiated.
You may also be interested in...
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.